A 7-month-old infant, with no known
food allergy or intolerance, presenting with
eczema lesions affecting many parts of his body, was diagnosed with
infantile eczema. A skin barrier defect, due to
filaggrin deficiency, was suspected. Prior treatment with
emollients was not effective and produced discomfort. After twice-daily application of
methylprednisolone aceponate (MPA) 0.1% (
Advantan(®)), in addition to temporary withdrawal of
emollients, for 10 days. At the follow-up examination, improvements in all
eczema lesions, scratching behavior and sleep quality were observed, and
eczema was considered almost clear and under control.
Advantan was prescribed to control new flares of
eczema, and heavy
emollients were recommended to treat residual dryness and damage from original lesions. No side effects of
Advantan were reported. In an infant with newly diagnosed
eczema,
Advantan was safe and effective in alleviating lesions and scratching severity and restoring sleep.